CRIPSR’s hype is not going down yet.
It also caught great interest from the industry and venture capitalists. The leading Biotechs includes:
- Editas, Boston-based and clozed a $120M found last August
- Intellia, also in Boston and raised $70M in September
- CRISPR Therapeutics, the European challenger, which closed a €79.5M round last April
Now CRISPR Therapeutics has just signed a massive €2.29Bn Deal.
The goal of this collaboration is to develop treatments aimed at the underlying genetic causes of human disease. It will start on discovering treatments to address the mutations and genes known to cause and contribute to Cystic fibrosis (the special focus of Vertex) and Sickle Cell Anemia.